A building component comprises: a first chamber locatable on or adjacent to an outer surface of a building or building element; a second chamber locatable on or adjacent to an inner surface of the building or building element; a two-phase working fluid comprising a gas-phase and a liquid-phase contained within the first chamber and/or the second chamber; at least one conduit configured to provide a path for the gas-phase of the working fluid to move between the first chamber and the second chamber; and at least one fluid transfer means configured to control transfer of the liquid-phase and/or the gas phase of the working fluid between the first chamber and the second chamber. The building component comprises an insulating configuration in which latent heat transfer between the first and second chambers is prevented or substantially prevented by the at least one fluid transfer means and at least one thermally conductive configuration in which latent heat transfer between the first and second chambers is permitted or substantially permitted by the at least one fluid transfer means. The at least one fluid transfer means has an inactive state in which transfer of the working fluid between the first and second chambers is prevented or substantially prevented and an active state in which transfer of the working fluid between the first and second chambers is permitted or substantially permitted. Switching the at least one fluid transfer means from the inactive state to the active state causes the building component to switch from the insulating configuration to the at least one thermally conductive configuration.
E04B 1/76 - Heat, sound or noise insulation, absorption, or reflectionOther building methods affording favourable thermal or acoustical conditions, e.g. accumulating of heat within walls specifically with respect to heat only
F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
F28D 20/02 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or using latent heat
A polymeric material comprising solid peroxide embedded therein. The polymeric material further comprises hydrogen peroxide which has been released from the solid peroxide. The amount of hydrogen peroxide has been increased by treating the polymeric material with ultrasound. As a result of the increased amount of hydrogen peroxide, the polymeric material has enhanced antimicrobial properties when compared with the same material without ultrasound treatment. Subsequent treatments with ultrasound may provide further increases in the amount of hydrogen peroxide. The polymeric material has uses as a wound dressing or on implantable devices.
A61L 15/26 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bondsDerivatives thereof
A61L 15/18 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
The present invention relates to drug delivery, more specifically, to polymersomes used as a drug delivery systems. The present invention also relates to polymersomes comprising a composition for use in treating, for example, ocular disorders and pulmonary disorders.
A Fusion Peptide for Activation of the APJ and / or GLP-1 Receptors This invention relates to a fusion peptide comprising a GLP-1 receptor agonist (GLP-1 RA) and an APJ receptor agonist; wherein the GLP-1 RA is covalently linked to the APJ receptor agonist by a link; and wherein the fusion peptide retains at least some activity of at least one of the GLP-1 RA and the APJ receptor agonist.
This invention relates to predicting a subject's responsiveness to Disease Modifying Anti-Rheumatic Drug therapy of rheumatoid arthritis. The invention provides an in vitro method for predicting responsiveness to a Disease Modifying Anti-Rheumatic Drug therapy in a subject, the method comprising the steps of: (a) providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker in the biological sample, wherein the first marker is a regulatory T cell having a CD45RA+FoxP3− phenotype; (c) correlating the presence, absence, or quantitative level of the first marker to the predicted responsiveness to the Disease Modifying Anti-Rheumatic Drug therapy in the subject.
The present invention relates to a method of diagnosing depression in a subject. Specifically, the present invention relates to diagnosing depression in a subject by providing a sample of the microbiome from the subject; determining the quantitative level or presence of one or more bacterial species in the sample; and diagnosing depression based on the quantitative level or presence of the one or more bacterial species in the sample.
The present invention relates to an isolated polypeptide that finds utility in generating an immune response against a virus in a subject. Also disclosed are immunogenic compositions comprising the isolated polypeptide, generating an immune response against a virus in a subject, and preventing or treating a viral infection in a subject, in particular a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
The present invention relates to a sensitizer-peptide conjugate for use in the treatment of cancer. In particular, the present invention relates to a sensitizer-peptide conjugate for use in the treatment of melanoma. The use of such sensitizer-peptide conjugate in photodynamic therapy or sonodynamic therapy is also disclosed. According to the present invention, there is provided a sensitizer-peptide conjugate for use in the treatment of cancer; wherein the sensitizer-peptide conjugate comprises at least one sensitizer and at least one peptide.
The present invention relates to compositions for use in the treatment of diabetes or obesity. In one embodiment, the present invention relates to a peptide analogue of pancreatic polypeptide (PP) for use in the treatment of diabetes or obesity. Also disclosed are methods of treatment of diabetes or obesity, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating diabetes or obesity.
UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (United Kingdom)
UNIVERSITY OF ULSTER (United Kingdom)
UCL BUSINESS LIMITED (United Kingdom)
Inventor
Redmond, Anthony William
Mulholland, Pádraig Joseph
Anderson, Roger Sproule
Garway-Heath, David Fitzgerald
Abstract
The present invention is concerned with a method and an instrument for measuring visual field sensitivity wherein the method relies on measuring, across a subject's visual field, the subject's response to a fixed-luminance stimulus, the area of which is modulated on subsequent stimulation; and said instrument is adapted to emit, at one or more locations across a subject's visual field, a fixed-luminance stimulus whose area is modulated on subsequent stimulation and wherein the instrument is also adapted to record the subject's response to said fixed-luminance stimulus by comparing the subject's response with the response in an age-matched normal group or by comparing the response to a prior determined baseline in order to identify any change in visual field sensitivity.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
12.
A METHOD OF PREDICTING RESPONSE TO TREATMENT WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG, AND/OR CLASSIFYING DISEASE ACTIVITY IN A SUBJECT WITH RHEUMATOID ARTHRITIS
The present invention relates to a method of predicting response to treatment with a disease-modifying anti-rheumatic drug, and/or classifying disease activity in a subject with rheumatoid arthritis by determining the quantitative level of one or more biomarkers and either predicting response to treatment with a disease-modifying anti-rheumatic drug, classifying disease activity, and/el or predicting response to treatment with a disease-modifying anti-rheumatic drug and classifying disease activity.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
This invention relates to predicting a subjects responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti-tumour necrosis factor therapy of rheumatoid arthritis in the subject.
A method of processing a digital image for use by a digital image classifier comprises: processing the digital image with computational models of a retinal ganglion cell (RGC) to produce sets of digital image features; and combining the sets of digital image features to produce a multi-channel retina model image. The method may be used in digital image classification and in training a digital image classifier. The creation and use of multi-channel retina model images improves the ability to detect pertinent image features during image classification and so improves the overall classification process.
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
15.
COMPOSITIONS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASE
The present invention relates to compositions for use in the treatment of neurological disease. In one embodiment, the present invention relates to a peptide analogue of xenin or gastric inhibitory polypeptide for use in the treatment of neurological disorders. Also disclosed are methods of treatment of neurological disease, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating neurological disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention provides polymeric particles comprising a matrix of a biocompatible polymer and polyethylene imine, said matrix having incorporated therein an anionic or hydrophobic sonosensitiser and, optionally, an immunomodulatory agent and/or an imaging agent. Such particles find use in methods of sonodynamic therapy, in particular in methods of combined sonodynamic therapy and immunotherapy, for example in the treatment of cancer, metastasis or micrometastasis derived from cancer. The invention is particularly suitable for the treatment of deep-sited, hard to treat tumours such as pancreatic cancer.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
09 - Scientific and electric apparatus and instruments
38 - Telecommunications services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific, research, audiovisual, teaching apparatus and instruments; apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; recorded and downloadable media, multimedia devices; computer software; application software; platform software; adaptive software; interactive software; AI software; software applications; software platforms; interactive multimedia programs. Telecommunications, multimedia messaging services; multimedia messaging services (MMS); providing access to multimedia content online; transmission of vision via interactive multimedia networks; transmission of multimedia content via the Internet; transmission of sound via interactive multimedia networks; transmission of data, audio, video and multimedia files; broadcasting of audiovisual and multimedia content via the Internet; transmission of sound and vision via satellite or interactive multimedia networks; audio, video and multimedia broadcasting via the Internet and other communications networks; providing online chatrooms for the transmission of messages, comments and multimedia content among users; transmission of data, audio, video and multimedia files, including downloadable files and files streamed over a global computer network. Education; providing of training; entertainment; sporting and cultural activities; multimedia publishing; multimedia library services; publication of multimedia material online; multimedia publishing of printed matter; multimedia publishing of electronic publications; multimedia entertainment software publishing services; audio, video and multimedia production, and photography; digital video, audio and multimedia entertainment publishing services; provision of multimedia entertainment programs by television, broadband, wireless and on-line services. Scientific and technological services and research and design relating thereto; research and design services.
The present invention relates to a method of isolating exosomes. Specifically, the invention relates to a method comprising the steps of providing a sample including exosomes; identifying a cell-surface polypeptide on the exosomes; and isolating the exosomes using the cell-surface polypeptide on the exosomes. The exosomes isolated from by the methods of the invention can be studied for the purposes of biomarker identification, for the understanding of biological function and disease, and to find ways to target them with therapeutics.
A pharmaceutical delivery device, comprising a cylindrical body formed from a plurality of concentrically arranged layers, each layer being formed from a biodegradable material and incorporating at least one active pharmaceutical agent. Optionally, the device comprises an outer layer, and inner layer and one or more intermediate layers, wherein at least one of the one or more intermediate layers is formed from a material having a greater rate of degradation that the inner and outer layers such that the inner and outer layers separate in use.
This invention relates to predicting a subject's responsiveness to Disease Modifying Anti-Rheumatic Drug therapy of rheumatoid arthritis. The invention provides an in vitro method for predicting responsiveness to a Disease Modifying Anti-Rheumatic Drug therapy in a subject, the method comprising the steps of: (a) providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker in the biological sample, wherein the first marker is a regulatory T cell having a CD45RA+FoxP3- phenotype; (c) correlating the presence, absence, or quantitative level of the first marker to the predicted responsiveness to the Disease Modifying Anti-Rheumatic Drug therapy in the subject.
The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these complexes and their use in methods of sonodynamic therapy and/or sonodynamic diagnosis. Such methods find particular use in the treatment of cancer, e.g. pancreatic cancer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to an isolated polypeptide that finds utility in generating an immune response against a virus in a subject. Also disclosed are immunogenic compositions comprising the isolated polypeptide, generating an immune response against a virus in a subject, and preventing or treating a viral infection in a subject, in particular a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
A lateral flow immunoassay device includes a porous test strip, a sampling channel having an inlet at a first end to receive a biomarker and an outlet at a second end, opposite the first end, the outlet communicating with the test strip. The sampling channel has an air vent opening at or adjacent the second end thereof, and a diluent reservoir having an outlet communicating with the test strip. The outlet of the sampling channel and the outlet of the diluent reservoir are sealed by a common removable seal to prevent communication between the sampling channel and the test strip, and the diluent reservoir and the test strip, until the seal is removed.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
The invention generally relates to sonodynamic therapy using microbubble-sonosensitiser complexes and, more specifically, to such therapy for the treatment of deeply-sited tumours and associated metastatic disease. In particular, the invention relates to a combination therapy in which sonodynamic treatment of deeply-sited tumours with microbubble-sonosensitiser complexes is combined with treatment using immune checkpoint inhibitors. It further relates to methods of sonodynamic therapy in which a sonodynamic-induced abscopal response modulates a systemic regression of metastatic disease. In such methods the abscopal response may be further enhanced by co-administration of an immune checkpoint inhibitor. The invention is particularly suitable for the treatment of pancreatic cancer (e.g. pancreatic ductal adenocarcinoma) and associated metastasis.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure concerns modulators of the NLRP3 inflammasome pathway, in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-1R1 and NLRP3, for use in the treatment or prophylaxis of inflammatory eye diseases such as glaucoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure concerns modulators of the NLRP3 inflammasome pathway, in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-1R1 and NLRP3.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
28.
A METHOD OF PREDICTING RESPONSE TO TREATMENT WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG, AND/OR CLASSIFYING DISEASE ACTIVITY IN A SUBJECT WITH RHEUMATOID ARTHRITIS
The present invention relates to a method of predicting response to treatment with a disease-modifying anti-rheumatic drug, and/or classifying disease activity in a subject with rheumatoid arthritis by determining the quantitative level of one or more biomarkers and either predicting response to treatment with a disease-modifying anti-rheumatic drug, classifying disease activity, and/or predicting response to treatment with a disease-modifying anti-rheumatic drug and classifying disease activity.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention relates to a method of diagnosing depression in a subject. Specifically, the present invention relates to diagnosing depression in a subject by providing a sample of the microbiome from the subject; determining the quantitative level or presence of one or more bacterial species in the sample; and diagnosing depression based on the quantitative level or presence of the one or more bacterial species in the sample.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
30.
Polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders
The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
32.
IMPROVEMENTS IN AND RELATING TO IMAGE CLASSIFICATION USING RETINAL GANGLION CELL MODELLING
A method of processing a digital image for use by a digital image classifier comprises: processing the digital image with computational models of a retinal ganglion cell (RGC) to produce sets of digital image features; and combining the sets of digital image features to produce a multi-channel retina model image. The method may be used in digital image classification and in training a digital image classifier. The creation and use of multi-channel retina model images improves the ability to detect pertinent image features during image classification and so improves the overall classification process.
The invention relates to a microbubble-chemotherapeutic agent complex comprising a microbubble carrying a combination of chemotherapeutic agents for use in a method of treating cancer in a patient, wherein said combination of chemotherapeutic agents comprises: (a) a 5-fluoropyrimidine or a derivative thereof; (b) irinotecan or a derivative thereof; and (c) a platinum-based chemotherapeutic agent or a derivative thereof; and wherein said method comprises simultaneous, separate or sequential administration of folinic acid or a derivative thereof. The invention is particularly suitable for use in the treatment of deep-sited tumours and associated metastatic disease, for example in the treatment of pancreatic cancer. The invention further relates to the microbubble- chemotherapeutic agent complexes themselves, to methods for their preparation and to pharmaceutical compositions which contain them, optionally in combination with folinic acid or a folinic acid derivative.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to a method of diagnosing or prognosing a neurological disorder in a subject. The method comprises determining the quantitative or qualitative level of one or more biomarkers in a biological sample from the subject; and diagnosing or prognosing the neurological disorder in the subject based on the quantitative or qualitative level of the or each biomarker in the biological sample.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
35.
PISCINE-DERIVED PYY PEPTIDES FOR USE IN TREATING A METABOLIC DISORDER
The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder; wherein the peptide is a piscine-derived PYY or fragment or analogue thereof.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
The present invention relates to a method of isolating exosomes. Specifically, the invention relates to a method comprising the steps of providing a sample including exosomes; identifying a cell-surface polypeptide on the exosomes; and isolating the exosomes using the cell-surface polypeptide on the exosomes. The exosomes isolated from by the methods of the invention can be studied for the purposes of biomarker identification, for the understanding of biological function and disease, and to find ways to target them with therapeutics.
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a sensitizer-peptide conjugate for use in the treatment of cancer. In particular, the present invention relates to a sensitizer-peptide conjugate for use in the treatment of melanoma. The use of such sensitizer-peptide conjugate in photodynamic therapy or sonodynamic therapy is also disclosed. According to the present invention, there is provided a sensitizer-peptide conjugate for use in the treatment of cancer; wherein the sensitizer-peptide conjugate comprises at least one sensitizer and at least one peptide.
A pharmaceutical delivery device, comprising a cylindrical body formed from a plurality of concentrically arranged layers, each layer being formed from a biodegradable material and incorporating at least one active pharmaceutical agent. Preferably the device comprises an outer layer, and inner layer and one or more intermediate layers, wherein at least one of said one or more intermediate layers is formed from a material having a greater rate of degradation that the inner and outer layers such that the inner and outer layers separate in use.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61J 3/10 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
The present disclosure relates to acidic sophorolipids and uses thereof, including for use in therapy and, in particular, in the treatment or prevention of cancer and associated pathologies.
A61P 35/04 - Antineoplastic agents specific for metastasis
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.
The invention provides polymeric particles comprising a matrix of a biocompatible polymer and polyethylene imine, said matrix having incorporated therein an anionic or hydrophobic sonosensitiser and, optionally, an immunomodulatory agent and/or an imaging agent. Such particles find use in methods of sonodynamic therapy, in particular in methods of combined sonodynamic therapy and immunotherapy, for example in the treatment of cancer, metastasis or micrometastasis derived from cancer. The invention is particularly suitable for the treatment of deep-sited, hard to treat tumours such as pancreatic cancer.
A lateral flow immunoassay device comprising a porous test strip, a sampling channel having an inlet at a first end to receive a biomarker and an outlet at a second end, opposite said first end, said outlet communicating with said test strip, said sampling channel having an air vent opening at or adjacent said second end thereof, and a diluent reservoir having an outlet communicating with said test strip, wherein said outlet of said sampling channel and said outlet of said diluent reservoir are sealed by a common removable seal to prevent communication between said sampling channel and said test strip and said diluent reservoir and said test strip until said seal is removed.
A method of generating an optical spectrum for a target object using a hand-held computing device such as a smartphone. The target is illuminated with a plurality of different colours of light one at a time in succession using the device's display. The device's video camera simultaneously records the corresponding sequence of coloured light reflected from the target object. Frame images are extracted from the digital video and a respective spectral value for the optical spectrum is calculated from a selected pixel from each frame image. A spectrometry system uses the optical spectrum to classify the target object using a subsumption-based classification technique and known reference spectra.
The present invention relates to a method for predicting a psychiatric disorder in a patient. Specifically, the invention relates to predicting a psychiatric disorder by measuring the nucleic acid methylation levels of one or more biomarkers in a sample from the patient in order to predict the psychiatric disorder in the patient. The methods of the invention also find utility in the diagnosis of a psychiatric disorder in a patient.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
45.
IMMUNE CHECKPOINT INHIBITOR IN COMBINATION WITH SONODYNAMIC THERAPY
The invention generally relates to sonodynamic therapy using microbubble-sonosensitiser complexes and, more specifically, to such therapy for the treatment of deeply-sited tumours and associated metastatic disease. In particular, the invention relates to a combination therapy in which sonodynamic treatment of deeply-sited tumours with microbubble-sonosensitiser complexes is combined with treatment using immune checkpoint inhibitors. It further relates to methods of sonodynamic therapy in which a sonodynamic-induced abscopal response modulates a systemic regression of metastatic disease. In such methods the abscopal response may be further enhanced by co-administration of an immune checkpoint inhibitor. The invention is particularly suitable for the treatment of pancreatic cancer (e.g. pancreatic ductal adenocarcinoma) and associated metastasis.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one sonosensitising agent and at least one chemotherapeutic agent. It further relates to the microbubble complexes themselves and to pharmaceutical compositions which contain them. The invention is particularly suitable for the treatment of deep-sited tumors, in particular pancreatic cancer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
The present disclosure concerns modulators of the NLRP3 inflammasome pathway,in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-1R1 and NLRP3, for use in the treatment or prophylaxis of inflammatory eye diseases such as glaucoma.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure concerns modulators of the NLRP3 inflammasome pathway,in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-1R1 and NLRP3.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
49.
Calcium peroxides nanoparticles as adjuvant therapy
2 nanoparticles, together with at least one photosensitiser, sonosensitiser, or radiosensitiser and, optionally, at least one pharmaceutical carrier or excipient.
A61K 31/78 - Polymers containing oxygen of acrylic acid or derivatives thereof
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A method of producing nanoscale materials comprising the steps of entraining liquid droplets containing at least one nanoparticle precursor within a gaseous stream, and passing said gaseous stream containing said liquid droplets through a non-thermal equilibrium plasma whereby said plasma interacts with said at least one nanoparticle precursor to produce nanoparticles within said droplets without substantial evaporation of the droplets and conveying the thus produced nanoparticles within said gaseous stream downstream of said plasma.
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
B22F 1/05 - Metallic powder characterised by the size or surface area of the particles
The present invention relates to a method of diagnosing or prognosing a neurological disorder in a subject. The method comprises determining the quantitative or qualitative level of one or more biomarkers in a biological sample from the subject; and diagnosing or prognosing the neurological disorder in the subject based on the quantitative or qualitative level of the or each biomarker in the biological sample.
The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder; wherein the peptide is a piscine-derived PYYor fragment or analogue thereof.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a sensitizer-peptide conjugate for use in the treatment of cancer. In particular, the present invention relates to a sensitizer-peptide conjugate for use in the treatment of melanoma. The use of such sensitizer-peptide conjugate in photodynamic therapy or sonodynamic therapy is also disclosed. According to the present invention, there is provided a sensitizer-peptide conjugate for use in the treatment of cancer; wherein the sensitizer-peptide conjugate comprises at least one sensitizer and at least one peptide.
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one sonosensitising agent and at least one chemotherapeutic agent. It further relates to the microbubble complexes themselves and to pharmaceutical compositions which contain them. The invention is particularly suitable for the treatment of deep-sited tumors, in particular pancreatic cancer.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these complexes and their use in methods of sonodynamic therapy and/or sonodynamic diagnosis. Such methods find particular use in the treatment of cancer, e.g. pancreatic cancer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to a minimally invasive diagnostic device. The invention finds utility in the field of minimally invasive medical devices for indicating the presence of an analyte in a sample to be tested. Specifically, the present invention relates to a minimally invasive diagnostic device comprising an array of microneedles formed from a microporous material and in fluid communication with a reservoir, wherein the reservoir comprises a visual indicator for indicating the presence of an analyte in a sample to be tested.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
57.
CALCIUM PEROXIDES NANOPARTICLES AS ADJUVANT THERAPY
The invention provides CaO2 nanoparticles having a p H-responsive coating for use in a method of adjuvant therapy of hypoxic tumour cells or tissues. The nanoparticles find particular use in enhancing cancer therapies that depend on oxygen to exert their effect, such as photodynamic therapy (PDT), sonodynamic therapy (SDT), and radiotherapy. The invention also provides pharmaceutical compositions containing the coated CaO2 nanoparticles, together with at least one photosensitiser, sonosensitiser, or radiosensitiser and, optionally, at least one pharmaceutical carrier or excipient.
An external transmitter apparatus for a transcutaneous energy transfer (TET) system for supplying power for use in energising an implantable medical device is disclosed, the apparatus comprising an external transmitter apparatus comprising a plurality of transmitter coils for delivering power transcutaneously to one of a plurality of receiver coils of an implantable receiver apparatus of the TET system when located in proximity thereto. The external transmitter apparatus is provided with power by a pulsed power supply. The coils of the external transmitter apparatus and the implantable receiver apparatus may be printed on flexible substrates. Also disclosed are methods of operating such a system, an external transmitter apparatus for use in such a system, an external transmitter apparatus and an implantable receiver apparatus including flexible coils.
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
H02J 7/02 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
H02J 7/34 - Parallel operation in networks using both storage and other DC sources, e.g. providing buffering
A composite pressure vessel comprising an inner normally gas impermeable liner that becomes gas permeable at a predetermined temperature, a load bearing intermediate layer configured to withstand the internal pressure exerted by the compressed gas to be stored in the vessel, and a thermally protective outer layer formed from a material having a lower thermal conductivity than the intermediate layer, whereby the thermally protective outer layer has a greater temperature gradient across its thickness than the intermediate layer when the vessel is exposed to fire.
A method of producing nanoscale materials comprising the steps of entraining liquid droplets containing at least one nanoparticle precursor within a gaseous stream, and passing said gaseous stream containing said liquid droplets through a non-thermal equilibrium plasma whereby said plasma interacts with said at least onenanoparticle precursor to produce nanoparticles within said droplets without substantial evaporation of the droplets and conveying the thus produced nanoparticles within said gaseous stream downstream of said plasma.
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
A photovoltaic device (10) comprising a photoactive body between two electrodes (contact 1, contact 2). The body comprises semiconductor particles (24) embedded in a semiconductor matrix (22). The particles and matrix are electronically or optically coupled so that charge carriers generated in the particles are transferred directly or indirectly to the matrix. The matrix transports positive charge carriers to one of the electrodes and negative charge carriers to the other electrode. The particles are configured so that they do not form a charge carrier transport network to either of the electrodes and so perform the function of charge carrier generation but not charge carrier transport.
H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
H01L 31/0384 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including other non-monocrystalline materials, e.g. semiconductor particles embedded in an insulating material
H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
A hand support for a bow comprising a body (2) adapted to be clamped around the shaft of a bow, said body incorporating a plurality of mounting points (4, 6, 8, 10), at least one strap (12) formed from an flexible material extending between two or more of said mounting points to define loops (44) through which one or more digits of the player's hand (50) can be inserted to provide enhanced grip on the bow. In one embodiment a single strap (12) is provided threaded through selected apertures along the length of the body to defined loops (44) at desired locations along the length of the body (2) through which selected digits of the player's hand (50) can be passed.
A headgear incorporating a flat flexible substrate comprising an electrical circuit embedded within the substrate, wherein the circuit comprises a plurality of electrodes. The headgear comprises a plurality of receptacles within which the substrate can be removably inserted therein and where the receptacles are positioned within the headgear such that the electrodes align with motor and sensorimotor areas of a user's head when worn. The headgear incorporates a plurality of apertures which extend through the receptacles, headgear and wherein the electrodes align with the apertures and are exposed to contact the user's head. The circuit is configured to perform an electrophysiological monitoring method.
The present invention relates to compositions for use in the treatment of neurological disease. In one embodiment, the present invention relates to a peptide analogue of xenin or gastric inhibitory polypeptide for use in the treatment of neurological disorders. Also disclosed are methods of treatment of of neurological disease, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating neurological disorders.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
65.
POLYPEPTIDES AND ANALOGUES THEREOF FOR USE IN THE TREATMENT OF DIABETES AND BONE DISORDERS
The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
This invention relates to a liquid sample collection apparatus comprising, a port for receiving a liquid sample, a collector for storing said liquid sample, at least one conduit connecting said port to said collector, and a sample detection apparatus comprising a sensor for detecting said liquid in said collector and generating an output depending on the quantity of said liquid detected in said collector, and a controller responsive to said sensor output and configured to determine that said sample has been collected when said sensor output indicates that a quantity of said liquid above a threshold amount is detected in said collector.
The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these complexes and their use in methods of sonodynamic therapy and/or sonodynamic diagnosis. Such methods find particular use in the treatment of cancer, e.g. pancreatic cancer.
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Method and Apparatus for Forming Double Curvature corrugated and surface textured panels A method of stretch forming a double curvature panel having corrugations or other surface features formed therein comprising providing a reconfigurable forming surface (4) defined by a flexible interpolator sheet (6) mounted on an array (8) of height adjustable pins (10), said interpolator sheet (6) having a profiled upper surface adapted to form corrugations or other surface features in a workpiece as it is stretched over the forming surface (4), adjusting the height of each pin (10) to suit the shape of the panel to be produced, placing a workpiece onto the forming surface and stretching the workpiece over the forming surface such that the profiled upper surface of the interpolator sheet (6) formed the desired corrugations or other surface features in the workpiece.
A pharmaceutical composition with a peptide analog of apelin, and a method of treatment for various conditions are described. An exemplary embodiment is a peptide analog comprising at least residues 2-13 of SEQ ID NO: 1 and further comprising at least a substitution or modification at residue 13 of SEQ ID NO: 1. A pharmaceutical composition comprising the peptide analog of the present invention and method of treatment for diabetes, stimulating insulin release, and moderating blood glucose excursions by administering the peptide analog of the present invention to a patient in need thereof are described.
An external transmitter apparatus for a transcutaneous energy transfer (TET) system for supplying power for use in energising an implantable medical device is disclosed, the apparatus comprising an external transmitter apparatus comprising a plurality of transmitter coils (17,19) for delivering power transcutaneously to one of a plurality of receiver coils (25,27) of an implantable receiver apparatus of the TET system when located in proximity thereto. The external transmitter apparatus is provided with power by a pulsed power supply (11). The coils of the external transmitter apparatus and the implantable receiver apparatus may be printed on flexible substrates. Also disclosed are methods of operating such a system, an external transmitter apparatus for use in such a system, an external transmitter apparatus and an implantable receiver apparatus including flexible coils.
This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole- 3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.
A photovoltaic device (10) comprising a photoactive body between two electrodes (contact 1, contact 2). The body comprises semiconductor particles (24) embedded in a semiconductor matrix (22). The particles and matrix are electronically or optically coupled so that charge carriers generated in the particles are transferred directly or indirectly to the matrix. The matrix transports positive charge carriers to one of the electrodes and negative charge carriers to the other electrode. The particles are configured so that they do not form a charge carrier transport network to either of the electrodes and so perform the function of charge carrier generation but not charge carrier transport.
H01L 51/42 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation
73.
METHOD AND APPARATUS FOR FORMING A COMPOUND CURVATURE METAL SKIN
A method of forming a compound curvature metal skin from a sheet metal blank comprising the steps of: •providing a blank (1) defining at least a sector of a truncated cone having a central axis of symmetry, a leading edge and a trailing edge; • providing an arcuate or annular punch (4) substantially corresponding in shape to an inner surface of the compound curvature metal skin and having an outer surface, a leading edge and an inner surface; • gripping the leading edge of the blank (1) between mating faces of a first blank holding means (6) located on a first side of the punch (4) adjacent the inner face of the punch; gripping the trailing edge of the blank (1) between mating faces of a second blank holding (8) means located on a second side of the punch (4, opposite to said first side and adjacent the outer face of the punch; • displacing the first and second blank holding means (6,8) with respect to the punch (4) in a single direction to draw the blank (1) over the punch (4) while permitting the blank (1) to flow between mating surfaces of at least one of the first and second blank holding means (6,8), comprising the steps of displacing each of the first and second blank holding means (6,8) with respect to the punch by different amounts and at different rates.
The present invention relates to a method of modifying a surface of a polymer. Specifically, the present invention relates to a method of modifying the topography of a polymer surface comprising the steps of providing a target source;providing a polymer substrate;providing a plasma environment at a specific pressure; sputtering the target source for a specific period; and condensing the sputtered target source at the polymer substrate. The present invention accordingly finds utility, for example, in functionalising a surface of a medical device formed from a polymeric material.
09 - Scientific and electric apparatus and instruments
14 - Precious metals and their alloys; jewelry; time-keeping instruments
16 - Paper, cardboard and goods made from these materials
18 - Leather and imitations of leather
25 - Clothing; footwear; headgear
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Information technology and audiovisual equipment; Measuring, detecting and monitoring instruments, indicators and controllers; Recorded content; Scientific research and laboratory apparatus, educational apparatus and simulators; Audio/visual and photographic devices; Communications equipment; Data processing equipment and accessories (electrical and mechanical); Data storage devices; Cases for electronic diaries; Computer networking and data communications equipment; DAB radios; Electric apparatus for commutation; Interactive computer software enabling exchange of information; Portable radios; Electronic notebooks; Electronic dictionaries; Electronic diaries; Recording apparatus; Calculators; Computers and computer hardware; Peripherals adapted for use with computers; Cases for pocket calculators; Computerised personal organisers; Data gloves; Data processing apparatus; Data processing equipment; Electronic calculators; Storage apparatus for computer data; Audio cassettes; Audio discs; Backup drives for computers; Binders for CDs; CD storage wallets; Computer discs; Computer memory devices; Electronic data carriers; Digital notepads; Digital recordings; Information carriers [electric or electronic]; Information storage apparatus [electric or electronic]; Memory sticks; Memory devices; Memory cards; USB flash drives; Electronic publications; Downloadable electronic publications; Electronic publications recorded on computer media; Audiovisual teaching apparatus; Scientific apparatus and instruments; Teaching and instructional apparatus; Education software. Jewellery; Jewellery boxes and watch boxes; Time instruments; Key rings and key chains; Badges of precious metal; Bracelets; Brooches [jewellery]; Cuff links and tie clips; Decorative articles [trinkets or jewellery] for personal use; Decorative pins [jewellery]; Earrings; Lapel pins; Medals; Scarf clips being jewelry; Alarm clocks; Cases for watches [presentation]; Clocks and watches. Printed matter; Stationery and educational supplies; Works of art and figurines of paper and cardboard, and architects' models; Bags and articles for packaging, wrapping and storage of paper, cardboard or plastics; Money holders; Paper and cardboard; Appointment books; Calendars; Chequebook cases; Chequebook covers; Daily planners; Educational publications; Greeting cards; Information booklets; Instructional manuals for teaching purposes; Leather covered diaries; Magazines [periodicals]; Manuals for instructional purposes; Newsletters; Newspapers; Paper report covers; Passport cases; Passport covers; Periodicals; Personal organisers; Posters; Printed lectures; Printed lessons; Printed matter for instructional purposes; Printed periodicals; Prospectuses; Promotional publications; Prints; Printed training materials; Printed teaching materials; Printed stationery; Printed research reports; Printed reports; Printed publications; Printed promotional material; Reference cards; Study guides; Wall calendars; Wall charts; Stationery; Files [stationery]; Writing stationery; Binders [stationery]; Gift stationery; Cases for stationery; Pocket books [stationery]; School supplies [stationery]; Document files [stationery]; Document holders [stationery]; Pens; Pencils; Erasers. Bags; Casual bags; Umbrella bags; Boot bags; Shoe bags; Canvas bags; Athletics bags; Sport bags; Travel bags; Duffle bags; Hand bags; Toiletry bags; Luggage, bags, wallets and other carriers; Umbrellas and parasols; Walking sticks; Art portfolios [cases]; Book bags; Briefcases and attache cases; Business card cases; Coin holders; Credit-card holders; Keycases; Make-up boxes; Luggage tags; Shopping bags; Purses; Pouches for holding make-up, keys and other personal items; Wallets. Clothing; Footwear; Headgear; Athletics vests; Bathing suits; Bathrobes; Belts [clothing]; Blazers; Cardigans; Coats; Dresses; Fleeces; Gloves [clothing]; Hooded sweatshirts; Knitwear [clothing]; Leisurewear; Printed t-shirts; Scarfs; Shirts; Shorts; Skirts; Socks; Sports caps and hats; Sports clothing [other than golf gloves]; Sweatbands; Tee-shirts; Tracksuit bottoms; Tracksuit tops; Trousers; Boots; Shoes; Sports shoes; Caps [headwear]; Hats; Head scarves; Headbands [clothing]; Sun visors; Sleep masks. Research (Business -); Market research; Advertising, promotional and marketing services; Business analysis, research and information services; Analysis of business statistics; Benchmarking services; Business analysis; Business information; Conducting of business research; Computerised business research; Business research and advisory services; Trade show and exhibition services; Event marketing; Design of marketing surveys; Business assistance, management and administrative services. Providing electronic publications; Publishing of electronic publications; Providing online electronic publications; Education, entertainment and sports; Publishing and reporting; Audio and video production, and photography; Education and instruction; Library services; Organisation of conferences, exhibitions and competitions; Sports and fitness; Arranging and presenting of live performances; Arranging for students to participate in recreational activities; Arranging of presentations for cultural purposes; Corporate hospitality (entertainment); Cultural services; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Hosting [organising] awards; Organisation of Webinars; Organizing cultural and arts events; Preparation of texts for publication; Production of documentaries; Providing recreation facilities; Services of schools [education]; Summer camps [entertainment and education]; Workshops for cultural purposes; Workshops for recreational purposes; Electronic publication of texts and printed matter, other than publicity texts, on the Internet; Issue of publications; Multimedia publishing of printed matter; Multimedia publishing of magazines, journals and newspapers; Publication of printed matter and printed publications; On-line publishing services; On-line publication of electronic books and journals (non-downloadable); Providing electronic publications; Providing on-line publications; Publication and editing of printed matter; Publication of instructional literature; Publication of educational texts; Publication of educational teaching materials; Publication of educational books; Publication of educational and training guides; Publication of documents in the field of training, science, public law and social affairs; Publication of books, magazines, almanacs and journals; Publication of printed matter and printed publications; Publication of printed matter in electronic form; Writing of texts; Reference libraries of literature and documentary records; University services; University education services; Academic examination services; Consultancy services relating to academic subjects; Arranging and conducting of lectures; Planning of lectures for educational purposes; Further education; Vocational education; Education services; Education information; Educational consultancy; Educational research; Educational demonstrations. Science and technology services; Engineering services; Medical and pharmacological research services; Advisory services relating to science; Advisory services relating to scientific research; Advisory services relating to technological research; Advisory services relating to the use of energy; Agricultural research; Analytical laboratory services; Archaeological research; Building research services; Chemical engineering; Chemical technological research; Compilation of scientific information; Computer technology consultancy; Conducting of technical feasibility studies; Consultancy services relating to technological research; Technological research; Engineering research; Research services; Research (Scientific -); Genetic research; Software research; Research laboratories; Clinical research; Biological research; Medical research; Testing, authentication and quality control; Design services; Advice relating to the design of computer hardware; Advisory services relating to building design; Advisory services relating to computer systems design; Advisory services relating to design engineering; Advisory services relating to industrial design; Commercial design services; Computer aided design services; Computer design research; Computer system design; Consultancy in the field of technological design; Design and creating web sites for others; Database design and development; Design and development of new technology for others; Design feasibility studies; IT services; Data duplication and conversion services, data coding services; IT consultancy, advisory and information services; IT security, protection and restoration; Software development, programming and implementation; Analytical services relating to computers; Computer analysis; Computer design and programming services; Computer research services.
09 - Scientific and electric apparatus and instruments
14 - Precious metals and their alloys; jewelry; time-keeping instruments
16 - Paper, cardboard and goods made from these materials
18 - Leather and imitations of leather
25 - Clothing; footwear; headgear
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Information technology and audiovisual equipment; Measuring, detecting and monitoring instruments, indicators and controllers; Recorded content; Scientific research and laboratory apparatus, educational apparatus and simulators; Audio/visual and photographic devices; Communications equipment; Data processing equipment and accessories (electrical and mechanical); Data storage devices; Cases for electronic diaries; Computer networking and data communications equipment; DAB radios; Electric apparatus for commutation; Interactive computer software enabling exchange of information; Portable radios; Electronic notebooks; Electronic dictionaries; Electronic diaries; Recording apparatus; Calculators; Computers and computer hardware; Peripherals adapted for use with computers; Cases for pocket calculators; Computerised personal organisers; Data gloves; Data processing apparatus; Data processing equipment; Electronic calculators; Storage apparatus for computer data; Audio cassettes; Audio discs; Backup drives for computers; Binders for CDs; CD storage wallets; Computer discs; Computer memory devices; Electronic data carriers; Digital notepads; Digital recordings; Information carriers [electric or electronic]; Information storage apparatus [electric or electronic]; Memory sticks; Memory devices; Memory cards; USB flash drives; Electronic publications; Downloadable electronic publications; Electronic publications recorded on computer media; Audiovisual teaching apparatus; Scientific apparatus and instruments; Teaching and instructional apparatus; Education software. Jewellery; Jewellery boxes and watch boxes; Time instruments; Key rings and key chains; Badges of precious metal; Bracelets; Brooches [jewelry]; Cuff links and tie clips; Decorative articles [trinkets or jewellery] for personal use; Decorative pins [jewellery]; Earrings; Lapel pins [jewellery]; Medals; Scarf clips being jewelry; Alarm clocks; Cases for watches [presentation]; Clocks and watches. Printed matter; Stationery and educational supplies; Works of art and figurines of paper and cardboard, and architects' models; Bags and articles for packaging, wrapping and storage of paper, cardboard or plastics; Money holders; Paper and cardboard; Appointment books; Calendars; Checkbook cases; Checkbook covers; Daily planners; Educational publications; Greeting cards; Information booklets; Instructional manuals for teaching purposes; Leather covered diaries; Magazines [periodicals]; Manuals for instructional purposes; Newsletters; Newspapers; Paper report covers; Passport cases; Passport covers; Periodicals; Personal organisers; Posters; Printed lectures; Printed lessons; Printed matter for instructional purposes; Printed periodicals; Prospectuses; Promotional publications; Prints; Printed training materials; Printed teaching materials; Printed stationery; Printed research reports; Printed reports; Printed publications; Printed promotional material; Reference cards; Study guides; Wall calendars; Wall charts; Stationery; Files [stationery]; Writing stationery; Binders [stationery]; Gift stationery; Cases for stationery; Pocket books [stationery]; School supplies [stationery]; Document files [stationery]; Document holders [stationery]; Stationery and educational supplies; Pens; Pencils; Erasers. Bags; Casual bags; Umbrella bags; Boot bags; Shoe bags; Canvas bags; Athletics bags; Sport bags; Travel bags; Duffle bags; Hand bags; Toiletry bags; Luggage, bags, wallets and other carriers; Umbrellas and parasols; Walking sticks; Art portfolios [cases]; Book bags; Briefcases and attache cases; Business card cases; Coin holders; Credit-card holders; Keycases; Make-up boxes; Luggage tags; Shopping bags; Purses; Pouches for holding make-up, keys and other personal items; Wallets. Clothing; Footwear; Headgear; Athletics vests; Bathing suits; Bathrobes; Belts [clothing]; Blazers; Cardigans; Coats; Dresses; Fleeces; Gloves [clothing]; Hooded sweatshirts; Jackets [clothing]; Knitwear [clothing]; Leisurewear; Printed t-shirts; Scarfs; Shirts; Shorts; Skirts; Socks; Sports caps and hats; Sports clothing [other than golf gloves]; Sweatbands; Tee-shirts; Tracksuit bottoms; Tracksuit tops; Trousers; Boots; Shoes; Sports shoes; Caps [headwear]; Hats; Head scarves; Headbands [clothing]; Sun visors; Sports caps; Sleep masks. Research (Business -); Market research; Advertising, marketing and promotional services; Business analysis, research and information services; Market research; Analysis of business statistics; Benchmarking services; Business analysis; Business information; Conducting of business research; Computerised business research; Business research and advisory services; Trade show and exhibition services; Event marketing; Design of marketing surveys; Business assistance, management and administrative services. Providing electronic publications; Publishing of electronic publications; Providing online electronic publications; Education, entertainment and sports; Publishing and reporting; Audio and video production, and photography; Education and instruction; Library services; Organisation of conferences, exhibitions and competitions; Sports and fitness; Arranging and presenting of live performances; Arranging for students to participate in recreational activities; Arranging of presentations for cultural purposes; Corporate hospitality (entertainment); Cultural services; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Hosting [organising] awards; Organisation of Webinars; Organizing cultural and arts events; Preparation of texts for publication; Production of documentaries; Providing recreation facilities; Services of schools [education]; Summer camps [entertainment and education]; Workshops for cultural purposes; Workshops for recreational purposes; Electronic publication of texts and printed matter, other than publicity texts, on the Internet; Issue of publications; Multimedia publishing of printed matter; Multimedia publishing of magazines, journals and newspapers; On-line publishing services; On-line publication of electronic books and journals (non-downloadable); Providing electronic publications; Providing on-line publications; Publication and editing of printed matter; Publication of instructional literature; Publication of educational texts; Publication of educational teaching materials; Publication of educational books; Publication of educational and training guides; Publication of documents in the field of training, science, public law and social affairs; Publication of books, magazines, almanacs and journals; Publication of printed matter and printed publications; Publication of printed matter in electronic form; Writing of texts; Reference libraries of literature and documentary records; University services; University education services; Academic examination services; Consultancy services relating to academic subjects; Arranging and conducting of lectures; Planning of lectures for educational purposes; Further education; Vocational education; Education services; Education information; Educational consultancy; Educational research; Educational demonstrations. Science and technology services; Engineering services; Medical and pharmacological research services; Advisory services relating to science; Advisory services relating to scientific research; Advisory services relating to technological research; Advisory services relating to the use of energy; Agricultural research; Analytical laboratory services; Archaeological research; Building research services; Chemical engineering; Chemical technological research; Compilation of scientific information; Computer technology consultancy; Conducting of technical feasibility studies; Consultancy services relating to technological research; Technological research; Engineering research; Research services; Research (Scientific -); Genetic research; Software research; Research laboratories; Clinical research; Biological research; Medical research; Testing, authentication and quality control; Design services; Advice relating to the design of computer hardware; Advisory services relating to building design; Advisory services relating to computer systems design; Advisory services relating to design engineering; Advisory services relating to industrial design; Commercial design services; Computer aided design services; Computer design research; Computer system design; Consultancy in the field of technological design; Design and creating web sites for others; Database design and development; Design and development of new technology for others; Design feasibility studies; IT services; Data duplication and conversion services, data coding services; IT consultancy, advisory and information services; IT security, protection and restoration; Software development, programming and implementation; Analytical services relating to computers; Computer analysis; Computer design and programming services; Computer research services.
The present invention relates to a process for the production of graphene and other 2- dimensional materials. The process involves the step of mixing and/or grinding a bulk layered material whilst simultaneously an ionic liquid is added continuously. Continuous addition of the ionic liquid can provide improved yields of the desired products and improved consistency of the quality of that product.
A method of producing a printed image comprising digital information embedded in a digital cover image. The method involves obtaining a frequency domain representation of the digital cover image, partitioning the frequency domain representation into blocks and selecting a sub-set of the frequency components of each block. A respective bit of the digital information is embedded in a respective one of the sub-sets by changing the polarity of the value of at least one of the respective frequency coefficients in the sub-set to create a modified block. The modified blocks are used to create a spatial domain representation of the digital cover image in which the digital information is embedded. The modified spatial domain representation of the digital cover image is then printed. The method is robust against distortion errors that can be introduced during print and scan operations and so the embedded digital information can readily be detected when the printed image is subsequently scanned.
A system is described herein for modifying a substrate using a downstream plasma process, comprising: a plasma head comprising a first electrode and a second electrode within a housing: with a gap provided between said first and second electrodes, and said housing having an outlet; means for supplying a voltage to at least one of the electrodes so as to create a plasma discharge between the electrodes and within the housing, means for positioning said substrate to be modified so that it is exposed to said outlet of the plasma head; means for directing said plasma discharge stream downstream from said gap between the electrodes, out of the outlet and into contact with at least a first portion of said substrate to be modified; means for moving either the substrate and/or said plasma head so that said substrate and said plasma head are being displaced relative to each other; wherein said means for moving said substrate and/or plasma head is configured to be moved and wherein said outlet is shaped so as to produce a variation between the surface modification of a first section of said portion of substrate and a second section of said portion of substrate. A method for modifying a substrate using a downstream plasma process is also described herein.
The invention relates to a peptide analogue comprising at least residues 2 –13 of SEQ ID NO: 1 and further comprising at least a substitution or modification at residue 13 of SEQ ID NO: 1. The invention also relates to a pharmaceutical composition comprising the peptide analogue of the present invention and methods of treatment of diabetes, stimulating insulin release and moderating blood glucose excursions comprising administering the peptide analogue of the present invention to a patient in need thereof.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
81.
A METHOD AND APPARATUS FOR PRESSING OILSEED TO EXTRACT OIL THEREFROM
A method of extracting oil from oilseed comprising pressing seeds within a screw press including a screw auger rotatably mounted within a cylindrical expeller body, wherein the expeller body comprises a feed section, a compression section, and a discharge section, wherein at least one outlet is provided in the expeller body, preferably in or adjacent the feed section of the expeller, said method comprising the step of controlling the temperature of at least the compression section of the expeller by means such that the temperature of the material within the compression section does not exceed the glass transition temperature of the seeds.
The present invention relates to an esculentin-2CHa peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture of a medicament for the treatment of diabetes, insulin resistance, obesity, and/or hypercholesterolemia; and methods of treating diabetes, insulin resistance, obesity, and/or hypercholesterolemia.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A reconfigurable stretch forming apparatus comprising an array of pins adapted to be individually adjustable in height to define a reconfigurable forming surface, a pair of counter-rotating workpiece gripping devices being provided on opposite sides of the array of pins, each gripping device having an arcuate support surface for supporting a workpiece and a clamp member for clamping a work piece against said arcuate support surface, drive means being provided for rotating the counter-rotating gripping devices in opposing directions to stretch the work piece over the forming surface.
A leak detection sensor comprising a pair of electrodes, each electrode being coated with an electrically insulating coating having fractures formed therein having a breadth of less than 500nm, whereby a current can flow between the electrodes when the electrodes are exposed to an electrically conductive fluid.
G01M 3/16 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using electric detection means
86.
METHOD AND SYSTEM FOR MODIFYING A SUBSTRATE USING A PLASMA
A method and system of modifying a substrate (8) using a plasma are described comprising providing a first electrode (4) and a second electrode (6); arranging the substrate such that a portion of the substrate is between the electrodes; supplying a voltage to at least one of the electrodes so as to create a plasma discharge between the electrodes which contacts at least said portion of the substrate, moving either the substrate and/or said second electrode such that said substrate and said second electrode are being linearly displaced relative to each other along an axis (80) of linear displacement during said movement; and wherein said second electrode is arranged relative to said axis of linear displacement such that said linear movement causes a first section of the portion of substrate to have a greater residence time between the electrodes during said linear displacement than a second section of said portion of the substrate. A method and system of modifying a substrate (8) using a plasma is also described comprising providing a first electrode (4) and a second electrode (6); arranging the substrate such that a portion of the substrate is between the electrodes; supplying a voltage to at least one of the electrodes so as to create a plasma discharge between the electrodes which contacts at least said portion of the substrate, moving either the substrate and/or said second electrode such that said substrate and said second electrode are being linearly displaced relative to each other along an axis (80) of linear displacement during said movement; and further comprising the step of rotating either the substrate or said second electrode about an axis of rotation during said relative linear displacement along said axis (80), so that a first section of the portion of substrate has a greater residence time between the electrodes than a second section of said portion of substrate.
A process of forming a tissue scaffold is described, the process comprising electrospinning polymer fibers from a spinneret onto a tissue scaffold template. In embodiments, the fibers are plasma-treated between the spinneret and the template. The scaffold may be constructed of alternating layers of aligned and randomly oriented fibers. The scaffold may be heat treated to control the mechanical properties of the scaffold, such as density, pore size and pore interconnectivity.
B29C 70/68 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts by incorporating or moulding on preformed parts, e.g. inserts or layers
A61L 31/14 - Materials characterised by their function or physical properties
D01D 10/00 - Physical treatment of man-made filaments or the like during manufacture, i.e. during a continuous production process before the filaments have been collected
A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
An automated smart system for forming a blast resistant structure comprises one or more remote blast sensors (2) connected to at least one actuator (4) arranged to actively deform a panel (5) of the structure from an initial configuration to a curved configuration (6) in response to sensing a blast (1).
E04C 2/32 - Building elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure formed of corrugated or otherwise indented sheet-like materialBuilding elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure composed of such layers with or without layers of flat sheet-like material
F42D 5/045 - Detonation-wave absorbing or damping means
A panel, wall or structure that can use its curvature to resist blast forces. Such a panel has a two-dimensional footprint defined by a height L and a curvature defined by a maximum lateral displacement x in a direction perpendicular to its footprint and towards a source of a blast. The curvature is chosen in the range of 0.001≤ x/L ≤ 0.5 so as to provide an improvement in blast resistance for the same panel thickness.
E04C 2/32 - Building elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure formed of corrugated or otherwise indented sheet-like materialBuilding elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure composed of such layers with or without layers of flat sheet-like material
F42D 5/045 - Detonation-wave absorbing or damping means
A method of producing a carbon fibre composite material is described comprising; shredding or chopping carbon fibre material; and extruding the shredded or chopped carbon fibre with thermoplastic, A method of producing a carbon fibre composite material is also described comprising: shredding, cutting or stamping carbon dry fibre material, arranging the shredded, cut or stamped material into a plurality of webs; arranging thermoplastic material between adjacent ones of said webs; within said webs; or on said webs; and heating and pressing said webs together to form an integrated composite component. A method of forming a carbon fibre composite is also described comprising; forming said composite from shredded carbon fibre material and thermoplastic material; arranging one or more thermoplastic film on one or more surface of the composite or arranging the composite in a thermoplastic charge bag; and melting the one or more film or charge bag onto the composite. A method of forming a carbon fibre composite is also described comprising providing a first thermoplastic film, and a second thermoplastic film, and bonding at least a first portion of a first surface of said first thermoplastic film to at least a first portion of a first surface of a second thermoplastic film.
C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material
B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
B29C 70/46 - Shaping or impregnating by compression for producing articles of definite length, i.e. discrete articles using matched moulds, e.g. for deforming sheet moulding compounds [SMC] or prepregs
B29B 9/14 - Making granules characterised by structure or composition fibre-reinforced
B29B 17/00 - Recovery of plastics or other constituents of waste material containing plastics
B29C 70/08 - Fibrous reinforcements only comprising combinations of different forms of fibrous reinforcements incorporated in matrix material, forming one or more layers, with or without non-reinforced layers
B32B 37/04 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the partial melting of at least one layer
B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
D01G 11/04 - Opening rags to obtain fibres for re-use
B29C 43/36 - Moulds for making articles of definite length, i.e. discrete articles
92.
THERAPEUTIC USES OF DOGFISH GLUCAGON AND ANALOGUES THEREOF
The present invention relates to peptides of 12 to 50 amino acids in length which incorporate the amino acid sequence MDNRRAK for use in the treatment of obesity, type-2 diabetes or metabolic syndrome.
A solar water heating apparatus comprising inner and outer concentrically arranged vessels; a cavity defined between the vessels by an outer wall of the inner vessel and an inner wall of the outer vessel; a liquid-to-vapour phase change material provided in the cavity; an inlet for delivering unhealed water to the Inner vessel; and an outlet tor withdrawing heated water from the inner vessel, and means for pumping the phase change material towards the inner wall of the outer vessel.
A method for the production of conjugated nanoparticles in a microfluidic device. The method comprises: adding a nanoparticle precursor to the microfluidic device through one or more flow channels;generating microplasma in the microfluidic device;causing the microplasma to interact with the nanoparticle precursor to generate nanoparticles; adding a conjugate material into the microfluidic device through one or more flow channels;and causing the nanoparticles to mixwith the conjugate material in a continuous flow to form conjugated nanoparticles.
A method of controlling a portable electronic device or activating or controlling a software application on a portable electronic device is disclosed. The method comprises: providing a source of a wireless signal; receiving said wireless signal at said portable electronic device; detecting variations in the signal received at the portable electronic device; using the portable electronic device to process said variations in the signal received so as to determine if the signal variations have resulted from interference caused by movement of an object in a region between the portable electronic device and the source of the wireless signal; and wherein the portable electronic device alters its operation or activates or controls a software application on the portable electronic device based on the determined movement of the object. The preferred embodiment enables a portable electronic device such as a smart phone to detect the movement of an object using a wireless signal from a WiFi router.
The invention relates to peptides and peptide derivatives based on the naturally occurring peptide xenin. The invention provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence, the peptide having one or more lysine residues substituted with a lipophilic substituent of 8-40 carbon atoms, optionally via a spacer. The present invention also provides a peptide of SEQ ID No. 1 or an analogue thereof which is able to stimulate insulin secretion and which has no more than 7 amino acid substitutions or deletions as compared to the native sequence and in which one or more of Lys4, Lys8, Arg11, Lys13, Phe17, Lys20, or Arg21 have been replaced with another amino acid which increases resistance of the peptide to enzymatic degradation. Further provided are molecules and formulations comprising these peptides and therapeutic uses of these peptides.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A woven formwork for construction of a structure is disclosed. The formwork comprises a three-dimensional woven fabric arranged so as to define one or more cavities into which an in-fill material can be inserted in order to construct said structure.
2 or/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
99.
AN IMMERSIVE INTERACTIVE VIDEO CONFERENCING, SOCIAL INTERACTION OR GAMING SYSTEM
An immersive interactive video conferencing, social interaction or gaming system is disclosed comprising a device having one or more video cameras. The video cameras are arranged to record a plurality of simultaneous first video images of a user and the user's environment. The device also comprises one or more video projectors which are arranged to project a plurality of second video images relating to video content from other users.
G03B 37/04 - Panoramic or wide-screen photographyPhotographing extended surfaces, e.g. for surveyingPhotographing internal surfaces, e.g. of pipe with cameras or projectors providing touching or overlapping fields of view
A protective panel takes the form of a cement mortar panel(1) made of cement mortar containing metal fibres and, optionally, polymer fibres. A core volume (2) of the panel (1) is reinforced by a network of 3D wire cells. The network of 3D wire cells may be defined by multiple layers of metal mesh that are fixedly connected or integrated together. Such protective panels (1) are capable of resisting fire, explosion and/or blast impact.
E04C 5/01 - Reinforcing elements of metal, e.g. with non-structural coatings
E04C 5/06 - Reinforcing elements of metal, e.g. with non-structural coatings of high bending resistance, i.e. of essentially three-dimensional extent, e.g. lattice girders
E04H 9/10 - Independent sheltersArrangement of independent splinter-proof walls
